Aquestive Therapeutics Inc (AQST) - Net Assets
Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has net assets worth $-33.66 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($160.43 Million) and total liabilities ($194.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aquestive Therapeutics Inc (AQST) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-33.66 Million |
| % of Total Assets | -20.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 286.02 |
Aquestive Therapeutics Inc - Net Assets Trend (2005–2025)
This chart illustrates how Aquestive Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore AQST total asset value for the complete picture of this company's asset base.
Annual Net Assets for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual net assets of Aquestive Therapeutics Inc from 2005 to 2025. For live valuation and market cap data, see AQST company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-33.66 Million | +44.04% |
| 2024-12-31 | $-60.16 Million | +43.51% |
| 2023-12-31 | $-106.49 Million | +10.18% |
| 2022-12-31 | $-118.55 Million | -44.34% |
| 2021-12-31 | $-82.13 Million | -69.36% |
| 2020-12-31 | $-48.50 Million | -692.18% |
| 2019-12-31 | $-6.12 Million | -160.73% |
| 2018-12-31 | $10.08 Million | +138.04% |
| 2017-12-31 | $-26.50 Million | -50.75% |
| 2016-12-31 | $-17.58 Million | -169.57% |
| 2006-12-31 | $25.26 Million | +441.54% |
| 2005-12-31 | $4.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aquestive Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43515500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $122.00K | % |
| Other Components | $413.21 Million | % |
| Total Equity | $-33.66 Million | 100.00% |
Aquestive Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aquestive Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Emerging Eastern Aviation Equipment Co Ltd Class A
SHE:002933
|
$512.07 Million |
|
Oron Group Investments & Holdings Ltd
TA:ORON
|
$512.25 Million |
|
Rusoro Mining Ltd
V:RML
|
$512.32 Million |
|
Tianjin Jieqiang Power Equipment Co
SHE:300875
|
$512.34 Million |
|
Vinh Hoan Corp
VN:VHC
|
$511.67 Million |
|
Yingkou Fengguang Advanced Material Co.Ltd.
SHE:301100
|
$511.57 Million |
|
Luoyang Jalon Micro-Nano New Materials Co Ltd
SHG:688357
|
$511.44 Million |
|
Invesco Quality Municipal Income Closed Fund
NYSE:IQI
|
$511.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aquestive Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -60,156,000 to -33,662,000, a change of 26,494,000.
- Net loss of 83,784,000 reduced equity.
- New share issuances of 100,654,000 increased equity.
- Other factors increased equity by 9,624,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-83.78 Million | -248.9% |
| Share Issuances | $100.65 Million | +299.01% |
| Other Changes | $9.62 Million | +28.59% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aquestive Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.72 | $4.12 | x |
| 2017-12-31 | $-1.32 | $4.12 | x |
| 2018-12-31 | $0.49 | $4.12 | x |
| 2019-12-31 | $-0.24 | $4.12 | x |
| 2020-12-31 | $-1.44 | $4.12 | x |
| 2021-12-31 | $-2.16 | $4.12 | x |
| 2022-12-31 | $-2.43 | $4.12 | x |
| 2023-12-31 | $-1.74 | $4.12 | x |
| 2024-12-31 | $-0.69 | $4.12 | x |
| 2025-12-31 | $-0.28 | $4.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aquestive Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -188.09%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-69.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -177.56% | -390.16% | 0.17x | 2.64x | $-8.75 Million |
| 2006 | -50.48% | -469.69% | 0.10x | 1.08x | $-15.28 Million |
| 2016 | 0.00% | -18.54% | 1.31x | 0.00x | $-7.84 Million |
| 2017 | 0.00% | -13.36% | 1.55x | 0.00x | $-6.29 Million |
| 2018 | -608.89% | -91.02% | 0.78x | 8.62x | $-62.38 Million |
| 2019 | 0.00% | -125.92% | 0.67x | 0.00x | $-65.63 Million |
| 2020 | 0.00% | -121.67% | 0.73x | 0.00x | $-50.93 Million |
| 2021 | 0.00% | -138.77% | 0.82x | 0.00x | $-62.33 Million |
| 2022 | 0.00% | -114.11% | 0.84x | 0.00x | $-42.55 Million |
| 2023 | 0.00% | -15.56% | 0.88x | 0.00x | $2.78 Million |
| 2024 | 0.00% | -76.68% | 0.57x | 0.00x | $-38.12 Million |
| 2025 | 0.00% | -188.09% | 0.28x | 0.00x | $-80.42 Million |
Industry Comparison
This section compares Aquestive Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $269,733,057
- Average return on equity (ROE) among peers: -33.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aquestive Therapeutics Inc (AQST) | $-33.66 Million | -177.56% | N/A | $512.05 Million |
| Aurora Cannabis Inc (ACB) | $219.71 Million | -5.90% | 0.47x | $201.62 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $14.43 Million |
| Akebia Ther (AKBA) | $131.00 Million | -46.35% | 0.09x | $273.24 Million |
| Alkermes Plc (ALKS) | $121.14 Million | -50.65% | 2.19x | $5.83 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $305.26 Million | -47.41% | 0.09x | $1.51 Billion |
| Amphastar P (AMPH) | $233.44 Million | 7.75% | 0.36x | $811.75 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.96 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -174.05% | 9.57x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $108.93 Million | 10.79% | 0.30x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $338.54 Million | -14.15% | 1.25x | $1.80 Billion |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more